Cart
sales@molnova.com
AGN 193109
CAS No. 171746-21-7
AGN 193109( —— )
Catalog No. M22422 CAS No. 171746-21-7
AGN 193109, a retinoid analog, is a potent and specific antagonist of RARs (Kds: 2 nM, 2 nM, and 3 nM for RARα, RARβ, and RARγ).AGN 193109 is completely RAR specific because it does not bind to or transactivate through any of the RXRs.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 1 mL x 10 mM in DMSO | 155 | In Stock |
|
| 2MG | 87 | In Stock |
|
| 5MG | 147 | In Stock |
|
| 10MG | 235 | In Stock |
|
| 25MG | 424 | In Stock |
|
| 50MG | 641 | In Stock |
|
| 100MG | 918 | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameAGN 193109
-
NoteResearch use only, not for human use.
-
Brief DescriptionAGN 193109, a retinoid analog, is a potent and specific antagonist of RARs (Kds: 2 nM, 2 nM, and 3 nM for RARα, RARβ, and RARγ).AGN 193109 is completely RAR specific because it does not bind to or transactivate through any of the RXRs.
-
DescriptionAGN 193109, a retinoid analog, is a potent and specific antagonist of RARs (Kds: 2 nM, 2 nM, and 3 nM for RARα, RARβ, and RARγ).AGN 193109 is completely RAR specific because it does not bind to or transactivate through any of the RXRs . AGN 193109 (100 nM) inhibits the TTNPB (a retinoic acid receptor agonist)-dependent morphological change in ECE16-1 cells. AGN193109 half-reverses retinoid-dependent growth suppression at 10 nM, and completely shows this effect at 100 nM in ECE16-1 cells. AGN193109 (100 nM) also eliminates TTNPB-induced decrease in levels of K5, K6, K14, K16, and K17 and increases in levels of K7, K8, and K19 .AGN 193109 (0.30 or 1.20 μmol/kg) by topical treatment significantly reduces both weight loss and cutaneous toxicity caused by oral TTNPB cotreatment. AGN 193109 (1.15 μmol/kg) does not cause overt toxicity and has no effect on spleen weight on the mice, but it suppresses TTNPB-induced increase in spleen weight of the mice. AGN 193109 also significantly reduces the cutaneous toxicity induced by ATRA.(In Vitro):AGN 193109 (0.1 and 1 μmol/L; 3 w) dose-dependently increases vascular smooth muscle cells (VSMCs) mineralization.AGN 193109 (100 nM; 10 d) induces human pluripotent stem cells (hPSCs) differentiate into olfactory placode cells and neurons.
-
In VitroAGN 193109 (0.1 and 1 μmol/L; 3 w) dose-dependently increases vascular smooth muscle cells (VSMCs) mineralization.AGN 193109 (100?nM; 10 d) induces human pluripotent stem cells (hPSCs) differentiate into olfactory placode cells and neurons.
-
In Vivo——
-
Synonyms——
-
PathwayMetabolic Enzyme/Protease
-
TargetRetinoid Receptor
-
RecptorRARα| RARβ| RARγ
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number171746-21-7
-
Formula Weight392.49
-
Molecular FormulaC28H24O2
-
Purity>98% (HPLC)
-
SolubilityDMSO:2 mg/mL (5.10 mM; Need warming)
-
SMILESCc1ccc(cc1)C1=CCC(C)(C)c2ccc(cc12)C#Cc1ccc(cc1)C(O)=O
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Johnson AT, et al. Synthesis and characterization of a highly potent and effective antagonist of retinoic acid receptors. J Med Chem. 1995 Nov 24;38(24):4764-7.
molnova catalog
related products
-
AM580
AM580 is a retinoic acid receptor agonist that is selective for RARα( IC50 : 8 nM ).
-
BMS493
BMS493 is an inverse agonist of the pan-retinoic acid receptor (RAR) that inhibits retinoic acid-induced differentiation, enhances the interaction of nuclear co-inhibitors with RARs, attenuates RA signaling, potentiates TPP-induced toxicity, and inhibits the increase in phospholipase A2 activity.
-
Fluorobexarotene
Fluorobexarotene possesses an apparent RXR binding affinity that is 75% greater than Bexarotene.?
